{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:01:26Z","timestamp":1792195286603,"version":"4.4.0"},"reference-count":125,"publisher":"Informa UK Limited","issue":"4","funder":[{"name":"Anusandhan National Research Foundation (ANRF), New Delhi","award":["ANRF\/PMP\/2025\/000324\/CS"],"award-info":[{"award-number":["ANRF\/PMP\/2025\/000324\/CS"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.1080\/13543784.2026.2640986","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:57:20Z","timestamp":1772726240000},"page":"273-294","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Tubulin polymerization inhibitors in early clinical studies as cancer therapeutics"],"prefix":"10.1080","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4107-1775","authenticated-orcid":false,"given":"Ahmed","family":"Kamal","sequence":"first","affiliation":[{"name":"Osmania University","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahaman","family":"Shaik","sequence":"additional","affiliation":[{"name":"Jamia Hamdard","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna Anjaneyulu","family":"Yakkalaa","sequence":"additional","affiliation":[{"name":"Jamia Hamdard","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.DEVCEL.2020.06.008"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13225650"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17568919.2025.2546774"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/S40001-024-01657-2"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-024-00545-8"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/CBDD.14513"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2024.2341630"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS17010121"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2115593119"},{"key":"e_1_3_6_12_1","unstructured":"Artico Alice Nicolai M. Anti-neoplastic effects of novel compounds on human head & neck squamous carcinoma cell lines. [cited 2025 Oct 16]. Available from: https:\/\/iris.uniroma1.it\/handle\/11573\/1614138"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS12082161"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.BCP.2021.114641"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.MOLSTRUC.2022.132723"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2023.2291390"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030341"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17091154"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108728"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1039\/D3MD00337J"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2025.1606848"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2024.2331015"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2025.2507384"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1039\/D5RA03611A"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/SLCT.202400539"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1039\/D4MD00541D"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867330666230622142505"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.20517\/CDR.2019.06"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/MED.20239"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.15252\/EMBJ.201899238"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/EMBOJ\/17.1.37"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.18632\/ONCOTARGET.14980"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJMECH.2018.12.030"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30163314"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16050749"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_SUPPL.E14619"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/S44321-025-00223-5"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118191"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41420-025-02679-3"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/BIOM12121843"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0937"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107932"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.3892\/BR.2019.1196"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.986"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-64610-7"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.2217\/FON.10.90"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS12010074"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1548997"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.05592"},{"key":"e_1_3_6_50_1","unstructured":"Khan A. Study of serial markers of biological response in rectal cancer patients receiving preoperative chemoradiotherapy with or without biological agents [Doctoral thesis]. UCL (University College London); 2017."},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2024.1303335"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS16071377"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/MED.21568"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00086"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES22081281"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1556245"},{"key":"e_1_3_6_57_1","unstructured":"SC-102 in advanced solid cancers - clinical trials registry - ICH GCP. [cited 2025 Oct 17]. Available from: https:\/\/ichgcp.net\/clinical-trials-registry\/NCT06710158"},{"key":"e_1_3_6_58_1","unstructured":"Characterization of and protection from neurotoxicity induced by oxaliplatin Bortezomib and epothilone-B | request PDF. [cited 2025 Oct 17]. Available from: https:\/\/www.researchgate.net\/publication\/259631390_Characterization_of_and_Protection_from_Neurotoxicity_Induced_by_Oxaliplatin_Bortezomib_and_Epothilone-B"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.4143\/CRT.2014.258"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3049"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115534"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2025.1565699"},{"key":"e_1_3_6_63_1","unstructured":"Administration D. Clinical trial endpoints for the approval of Cancer drugs and biologics guidance for industry. 2018. Available from: https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htmand\/orhttps:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15133308"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-06894-3"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-023-42479-W"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.15_SUPPL.3587"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.617874"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.32.15_SUPPL.8054"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq708"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03924-X"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_SUPPL.E24303"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0166"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00210-025-04125-8\/METRICS"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.6644"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.8_SUPPL.TPS128"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14122850"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2715"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14806"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1634\/THEONCOLOGIST.2015-0276"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40265-019-01175-0"},{"key":"e_1_3_6_82_1","unstructured":"FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer | FDA. [cited 2025 Oct 17]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00720"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.BULCAN.2015.02.007"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.020"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/S12672-025-01820-Z"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.12.008"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10637-011-9702-9"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.07.024"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00280-008-0727-5"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1096"},{"key":"e_1_3_6_92_1","unstructured":"Plinabulin improves survival and duration of response in advanced Non_Small cell lung cancer. [cited 2025 Nov 23]. Available from: https:\/\/jons-online.com\/special-issues-and-supplements\/2017\/best-practices-in-immunotherapy-june-july-2017-vol-8\/plinabulin-improves-survival?utm_source=chatgpt.com"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2023.2287520"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES21111468"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13246194"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2007-0027"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.3390\/MD21010038"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10637-024-01458-8"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1021\/ACSOMEGA.8B00996"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2021.692970"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACCAS.2020.02.014"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/JAT.4521"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.1186\/S40364-024-00641-6"},{"key":"e_1_3_6_104_1","unstructured":"ZD6126 | cancer research | American association for cancer research. [cited 2025 Nov 16]. Available from: https:\/\/aacrjournals.org\/cancerres\/article\/62\/24\/7247\/509496\/ZD6126A-Novel-Vascular-targeting-Agent-That-Causes"},{"key":"e_1_3_6_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-008055232-3.61615-0"},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.VPH.2015.05.004"},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.1293\/TOX.2022-0143"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00280-023-04580-1"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.1021\/ACSCHEMNEURO.2C00324"},{"key":"e_1_3_6_110_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200221666200226123638"},{"key":"e_1_3_6_111_1","doi-asserted-by":"publisher","DOI":"10.3892\/OL.2017.5986"},{"key":"e_1_3_6_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JDDST.2022.104070"},{"key":"e_1_3_6_113_1","doi-asserted-by":"publisher","DOI":"10.20517\/CDR.2020.81"},{"key":"e_1_3_6_114_1","doi-asserted-by":"publisher","DOI":"10.3346\/JKMS.2010.25.11.1574"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.1416418112"},{"key":"e_1_3_6_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/CTM2.70313"},{"key":"e_1_3_6_117_1","doi-asserted-by":"publisher","DOI":"10.1039\/D3NP00053B"},{"key":"e_1_3_6_118_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1602529"},{"key":"e_1_3_6_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04125-8"},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS26104701"},{"key":"e_1_3_6_121_1","doi-asserted-by":"publisher","DOI":"10.3389\/FNAGI.2019.00204"},{"key":"e_1_3_6_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRANON.2023.101821"},{"key":"e_1_3_6_123_1","doi-asserted-by":"publisher","DOI":"10.1186\/S12964-022-00838-Y"},{"key":"e_1_3_6_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CANLET.2009.09.020"},{"key":"e_1_3_6_125_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13040920"},{"key":"e_1_3_6_126_1","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.JNATPROD.6B00944"},{"key":"e_1_3_6_127_1","doi-asserted-by":"publisher","DOI":"10.1021\/CB400461J"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2640986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:38:29Z","timestamp":1775817509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2640986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,3]]}},"alternative-id":["10.1080\/13543784.2026.2640986"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2640986","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}